Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Unspecified Adult Solid Tumor, Protocol Specific 2Uterine Cervical Neoplasms 1Sarcoma 1Neuroma, Acoustic 1Neurofibromatosis 2 1Esophageal Squamous Cell Carcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Cisplatin 45Radiotherapy 32Fluorouracil 27Paclitaxel 26Irinotecan 17Docetaxel 16Oxaliplatin 11Carboplatin 10pembrolizumab 9Cetuximab 8tislelizumab 7Surgical Procedures, Operative 7Neoadjuvant Therapy 7Drug Therapy 7Radiation 6Leucovorin 6sintilimab 5Nivolumab 5Immunohistochemistry 5Chemotherapy, Adjuvant 5Capecitabine 5nedaplatin 3durvalumab 3camrelizumab 3S 1 (combination) 3Magnetic Resonance Spectroscopy 3Gene Expression Profiling 3Gemcitabine 3Fluorodeoxyglucose F18 3Erlotinib Hydrochloride 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Esophageal Squamous Cell Carcinoma × Endostatins × Clear all
NCT02350517 2023-02-16

Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer

Sun Yat-sen University

Phase 2 Completed
52 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡